Invivotek completes solar farm and facility expansion

Provides a cleaner, renewable energy source to reduce costs and lessen the CRO facility's impact on the environment.

Invivotek joins many other pharmaceutical and biotech companies worldwide who have made a commitment to invest in solar power. This project advances the efforts of GBG to reduce high energy costs associated with research and improve their environmental profile. "Construction of the solar farm at Invivotek's research facility will not only reduce its carbon footprint, but it's also a good business decision," said Dr Eli Mordechai, CEO of Genesis Biotechnology Group. "We are committed to good stewardship, not only of our clients' projects, but also of our community and the environment."

The solar system is expected to produce over 1.2 million kilowatt hours per year. The savings to Invivotek will be in excess of $230,000 per year (enough to power 127 households for one year) and will provide over 60% of Invivotek's energy needs.